Scilex Holding Company (SCLXW)

USD 0.21

(-23.88%)

EBITDA Summary of Scilex Holding Company

  • Scilex Holding Company's latest annual EBITDA in 2023 was -109.1 Million USD , down -117.01% from previous year.
  • Scilex Holding Company's latest quarterly EBITDA in 2024 Q2 was -14.61 Million USD , down -57.82% from previous quarter.
  • Scilex Holding Company reported an annual EBITDA of -9.3 Million USD in 2022, down -45.58% from previous year.
  • Scilex Holding Company reported an annual EBITDA of -44.87 Million USD in 2021, down -1.84% from previous year.
  • Scilex Holding Company reported a quarterly EBITDA of -14.61 Million USD for 2024 Q2, down -57.82% from previous quarter.
  • Scilex Holding Company reported a quarterly EBITDA of -19.16 Million USD for 2023 Q1, down -2.44% from previous quarter.

Annual EBITDA Chart of Scilex Holding Company (2023 - 2019)

Historical Annual EBITDA of Scilex Holding Company (2023 - 2019)

Year EBITDA EBITDA Growth
2023 -109.1 Million USD -117.01%
2022 -9.3 Million USD -45.58%
2021 -44.87 Million USD -1.84%
2020 -31.48 Million USD 76.59%
2019 -134.48 Million USD 0.0%

Peer EBITDA Comparison of Scilex Holding Company

Name EBITDA EBITDA Difference
Amgen Inc. 12.23 Billion USD 100.892%
AstraZeneca PLC 12.97 Billion USD 100.841%
Biogen Inc. 2.37 Billion USD 104.59%
Gilead Sciences, Inc. 10.49 Billion USD 101.039%
MIRA Pharmaceuticals, Inc. - USD Infinity%
Scilex Holding Company -109.1 Million USD -0.0%